Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.8
5.6
Journals
IJMS
Special Issues
Targeted Therapy for Immune Diseases
ijms-logo
Submit to Special Issue Submit Abstract to Special Issue Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Targeted Therapy for Immune Diseases

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Immunology".

Deadline for manuscript submissions: 20 September 2024 | Viewed by 2662

Special Issue Editor

Dr. Alexey Sarapultsev

E-Mail Website
Guest Editor
1. Institute of Immunology and Physiology, Ural Branch of the Russian Academy of Science, 620049 Ekaterinburg, Russia
2. Russian–Chinese Education and Research Center of System Pathology, South Ural State University, 454080 Chelyabinsk, Russia
Interests: anxiety; COVID-19; dentistry; depression; inflammation; pathophysiology; pediatric dentistry; psychological distress; PTSD; stress
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Immune diseases encompass a range of disorders caused by abnormal immune system responses, including autoimmune diseases, allergies, and immunodeficiencies. These conditions significantly impact patients' quality of life and overall health. While traditional treatment approaches often focus on symptom management, targeted therapy offers a more precise and effective treatment strategy. Objective: This special issue aims to explore the latest research advancements and applications in targeted therapy for immune diseases. We welcome contributions from diverse disciplines, including immunology, pharmacology, molecular biology, and clinical medicine, to shed light on innovative approaches and therapeutic interventions. Scope: This special issue will cover a wide range of topics related to targeted therapy for immune diseases, including but not limited to: Novel therapeutic targets and mechanisms: Investigating new targets and understanding the underlying mechanisms involved in immune diseases to develop targeted therapies. Precision medicine approaches: Exploring personalized treatment strategies based on individual patient characteristics, such as genetic profiles, immune system status, and disease subtypes. Immunomodulatory therapies: Highlighting the development and application of immunomodulatory agents, including monoclonal antibodies, small molecules, and gene therapies, for immune disease treatment.

Potential Hot Topics:

  • Targeted biologics for autoimmune diseases;
  • Immune checkpoint inhibitors in cancer immunotherapy;
  • Gene therapy for immunodeficiency disorders;
  • Nanoparticle-based drug delivery systems for immune diseases;
  • Immunomodulatory effects of gut microbiota;
  • Precision medicine in the treatment of allergic diseases;
  • Immune cell engineering for adoptive cell therapy;
  • Targeting cytokine signaling pathways in autoimmune disorders;
  • Immunotherapy approaches for viral infections;
  • Biomarkers for predicting response to immune-based therapies.

Dr. Alexey Sarapultsev
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • targeted therapy
  • immune diseases
  • biologics
  • immunotherapy
  • precision medicine
  • nanoparticles
  • biomarkers

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 614 KiB  
Article
Applicability of a Chemiluminescence Immunoassay to Screen Postmortem Bile Specimens and Its Agreement with Confirmation Analysis
by Martina Franzin, Rachele Ruoso, Monica Concato, Davide Radaelli, Stefano D’Errico and Riccardo Addobbati
Int. J. Mol. Sci. 2024, 25(7), 3825; https://doi.org/10.3390/ijms25073825 - 29 Mar 2024
Viewed by 540
Abstract
Bile has emerged as an alternative matrix for toxicological investigation of drugs in suspected forensic cases of overdose in adults and intoxications in children. Toxicological investigation consists in screening and, subsequently, confirming the result with specific techniques, such as liquid chromatography with tandem [...] Read more.
Bile has emerged as an alternative matrix for toxicological investigation of drugs in suspected forensic cases of overdose in adults and intoxications in children. Toxicological investigation consists in screening and, subsequently, confirming the result with specific techniques, such as liquid chromatography with tandem mass spectrometry (LC-MS/MS). As there is no screening test on the market to test postmortem bile specimens, the novelty of this study was in investigating the applicability of a chemiluminescence immunoassay, designed for other matrices and available on the market, on bile and validate its use, testing the agreement with LC-MS/MS analysis. Bile specimens were obtained from 25 forensic cases of suspected death from overdose and intoxication. Sample preparation for bile screening consists simply in centrifugation and dilution. Confirmation analysis allows simultaneous identification of 108 drugs and was validated on bile. Kappa analysis assessed a perfect agreement (0.81–1) between the assays for benzodiazepines, methadone, opiates, cocaine, oxycodone, cannabinoids, buprenorphine and pregabalin; a substantial agreement (0.41–0.6) was reported for barbiturates. No agreement was assessed for amphetamines, due to an abundance of putrefactive amines in postmortem specimens. In conclusion, this fast and easy immunoassay could be used for initial screening of bile specimens, identifying presence of drugs, except amphetamines, with reliability. Full article
(This article belongs to the Special Issue Targeted Therapy for Immune Diseases)
►▼ Show Figures

Figure 1

12 pages, 695 KiB  
Article
Development and Validation of an HPLC-UV Method for the Quantification of Acyclovir and Ganciclovir in the Plasma of Pediatric Immunocompromised Patients
by Martina Franzin, Rachele Ruoso, Rossella Del Savio and Riccardo Addobbati
Int. J. Mol. Sci. 2024, 25(5), 2685; https://doi.org/10.3390/ijms25052685 - 26 Feb 2024
Viewed by 577
Abstract
Acyclovir and ganciclovir comprise the prophylaxis and treatment of herpesvirus and cytomegalovirus infections occurring in immunocompromised patients. Their therapeutic drug monitoring is fundamental because of interindividual variability leading to side effects and drug resistance and is performed through several techniques, such as liquid [...] Read more.
Acyclovir and ganciclovir comprise the prophylaxis and treatment of herpesvirus and cytomegalovirus infections occurring in immunocompromised patients. Their therapeutic drug monitoring is fundamental because of interindividual variability leading to side effects and drug resistance and is performed through several techniques, such as liquid chromatography coupled with UV spectrophotometry (HPLC-UV) or mass spectrometry (LC-MS/MS). Therefore, we developed and validated a low-cost, non-time-consuming, and low-sample-consuming HPLC-UV method. Briefly, 100 µL of sample was used for sample preparation, mainly consisting of precipitation through organic solvent. In total, 20 µL was injected into the instrument. Chromatographic separation was obtained eluting mobile phases A (10 mM ammonium formiate 0.01% formic acid) and B (acetonitrile) on a Poroshell 120 SB-C8 2.1 × 150 mm, 2.7 µm for 12 min isocratically (97:3; A:B) at a flow rate of 0.2 mL/min. The linearity range (0.5–40 mg/L) of the method allowed us to quantify both the Cmin and Cmax of acyclovir and ganciclovir. Plasma concentrations measured on a small cohort of patients undergoing acyclovir (31) and ganciclovir (9) treatment by the proposed method and the LC-MS/MS methods, already in use, were significantly correlated. The proposed HPLC-UV method may be implemented in diagnostics as an alternative method in case of the unavailability of the LC-MS/MS system. Full article
(This article belongs to the Special Issue Targeted Therapy for Immune Diseases)
►▼ Show Figures

Figure 1

18 pages, 5723 KiB  
Article
Thymosin β4 Regulates the Differentiation of Thymocytes by Controlling the Cytoskeletal Rearrangement and Mitochondrial Transfer of Thymus Epithelial Cells
by Yuyuan Ying, Nana Tao, Fengjie Zhang, Xunuo Wen, Meiru Zhou and Jianli Gao
Int. J. Mol. Sci. 2024, 25(2), 1088; https://doi.org/10.3390/ijms25021088 - 16 Jan 2024
Viewed by 843
Abstract
The thymus is one of the most crucial immunological organs, undergoing visible age-related shrinkage. Thymic epithelial cells (TECs) play a vital role in maintaining the normal function of the thymus, and their degeneration is the primary cause of age-induced thymic devolution. Thymosin β4 [...] Read more.
The thymus is one of the most crucial immunological organs, undergoing visible age-related shrinkage. Thymic epithelial cells (TECs) play a vital role in maintaining the normal function of the thymus, and their degeneration is the primary cause of age-induced thymic devolution. Thymosin β4 (Tβ4) serves as a significant important G-actin sequestering peptide. The objective of this study was to explore whether Tβ4 influences thymocyte differentiation by regulating the cytoskeletal rearrangement and mitochondrial transfer of TECs. A combination of H&E staining, immunofluorescence, transmission electron microscopy, RT-qPCR, flow cytometry, cytoskeletal immunolabeling, and mitochondrial immunolabeling were employed to observe the effects of Tβ4 on TECs’ skeleton rearrangement, mitochondrial transfer, and thymocyte differentiation. The study revealed that the Tβ4 primarily regulates the formation of microfilaments and the mitochondrial transfer of TECs, along with the formation and maturation of double-negative cells (CD4−CD8−) and CD4 single-positive cells (CD3+TCRβ+CD4+CD8−) thymocytes. This study suggests that Tβ4 plays a crucial role in thymocyte differentiation by influencing the cytoskeletal rearrangement and mitochondrial transfer of TECs. These effects may be associated with Tβ4’s impact on the aggregation of F-actin. This finding opens up new avenues for research in the field of immune aging. Full article
(This article belongs to the Special Issue Targeted Therapy for Immune Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop